Active substance
Sevoflurane
- SFDA 9
- US FDA 6
- Health Canada 3
- WHO EML 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HALURAN inhalation solution | inhalation solution · Inhalation use | 1 Bottle | SAR 428.80 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid | |
| SEVOFLURANE Inhalation Anesthetic | 250 ml | Inhalation vapour, liquid · Inhalation use | 1 Bottle | SAR 477.55 | NCE · Prescription | BAXTER HEALTHCARE CORPORATION | Valid |
| SEVORANE INHAL.ANESTHESIA Plastic BOTTLE | 100 % | Inhalation vapour, liquid · Inhalation use | 1 Bottle | SAR 514.15 | NCE · Prescription | Abbvie Limited | Valid |
| SEVORANE INHAL.ANESTHESIA aluminum BOTTLE | 100 % | Inhalation vapour, liquid · Inhalation use | 1 Bottle | SAR 734.50 | NCE · Prescription | Abbvie Limited | Valid |
| SOJOURN 100% VAPOUR LIQUID FOR INHALATION | 100 % | Inhalation vapour, liquid · Inhalation use | 1 Inhaler | SAR 318.05 | NCE · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| SEVOFLURANE100%LIQUID FOR INH.ANESTHESIA | Inhalation vapour, liquid · Inhalation use | 1 Bottle | SAR 597.40 | NCE · Prescription | BAXTER HEALTHCARE | Withdrawn by MAH · Not Marketed | |
| SEVORANE INHAL.ANESTHESIA BOTTLE | Inhalation vapour, liquid · Inhalation use | 1 Bottle | SAR 734.50 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed | |
| SEVORANE INHAL.ANESTHESIA BOTTLE | Inhalation vapour, liquid · Inhalation use | 1 Bottle | SAR 734.50 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed | |
| SOJOURN 100% VAPOUR LIQUID FOR INHALATION | 100 % | Inhalation vapour, liquid · Inhalation use | 1 Inhaler | SAR 476.45 | NCE · Prescription | PIRAMAL CRITICAL CARE INC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ULTANE | 100% | liquid · inhalation | ABBVIE | Prescription | 7 Jun 1995 |
| SEVOFLURANE | 100% | liquid · inhalation | BAXTER HLTHCARE | Prescription | 2 Jul 2002 |
| SOJOURN | 100% | liquid · inhalation | PIRAMAL CRITICAL | Prescription | 2 May 2007 |
| SEVOFLURANE | 100% | liquid · inhalation | HALOCARBON PRODS | Prescription | 19 Nov 2007 |
| SEVOFLURANE | 100% | liquid · inhalation | SHANGHAI HENGRUI | Prescription | 3 Nov 2015 |
| SEVOFLURANE | 100% | liquid · inhalation | SHANDONG | Prescription | 18 Aug 2023 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SEVOFLURANE | 02265974 | 99.97 % | LIQUID · INHALATION | BAXTER CORPORATION |
| SEVOFLURANE | 02307766 | 99.97 % / W/W | LIQUID · INHALATION | PIRAMAL CRITICAL CARE INC |
| SEVORANE AF | 02172763 | 99.97 % | LIQUID · INHALATION | ABBVIE CORPORATION |
WHO WHO Model List of Essential Medicines (2025)
- 1.1.1. General anaesthetics and oxygen > Inhalational medicines · core
Anaesthetics and therapeutic gases
Respiratory > Inhalation > liquid:
Safety signals and safety-related labeling changes
- EMA PRAC 9 Jul 2026 PRAC signal: Acute encephalopathy in patients carrying the mitochondrial DNA variant m.11232T>C
Action for MAH: update of the product information: No - US FDA 3 Feb 2025 ULTANE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 13 Feb 2020 PRAC signal: Diabetes insipidus
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.